Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.
|Number of pages||6|
|Journal||Current Opinion in Endocrine and Metabolic Research|
|Publication status||Published - Jun 2021|
Bibliographical noteFunding Information:
WWH received speaker fees from Novartis – AAA, Ipsen and Pfizer and research support from Ipsen .